RhoVac receives approval in Sweden to start clinical phase IIb trial
RhoVac AB ("RhoVac") announces today, on June 22[nd], 2020, that the company has received approval from all regulatory authorities in Sweden, which means that the clinical IIb study in prostate cancer ("BRaVac") can also be started in Sweden. The clinical phase IIb trial is an international study that is expected to recruit at least 175 patients in six European countries (Denmark, Finland, Sweden, the United Kingdom, Belgium and Germany) as well as in the United States.BRaVac is a randomized, placebo-controlled and double-blind study, with the primary study aim to evaluate whether treatment